|Bid||260.00 x 800|
|Ask||291.00 x 1000|
|Day's Range||259.71 - 270.36|
|52 Week Range||196.78 - 380.76|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||39.92|
|Earnings Date||Apr 22, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||326.25|
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session.
Health care, which makes up nearly 18% of American GDP, has long been a fruitful hunting ground for investors seeking growth. And medical-tech and medical-device stocks have always been particularly compelling niches.Not only do these companies ride the coattails of inexorable health-care spending, but their commitment to research and development can create new industries that they can in turn dominate.It's not an easy time right now, of course. The COVID-19 outbreak has taken a chunk out of every sector and almost every industry, with only a few "coronavirus stocks" enjoying any meaningful gains. Medical devices have at least been better than the market, which has declined by about 29% in this bear market so far, as measured by the S&P; 500\. But the iShares U.S. Medical Devices ETF (IHI) still has been cut to the tune of 25% in the same time frame.That could provide investors with a chance to buy medical-device stocks and other med-tech plays at a significant discount, however. While their growth might be stunted in the short-term, their longer-term prospects are likely to improve again once the COVID-19 threat is contained - and a few are seeing additional business in the wake of the outbreak.Here, we look at six med-tech and medical-device stocks to buy. SEE ALSO: 10 Health and Pharmaceutical Companies Fighting the Coronavirus
After reading Illumina, Inc.'s (NasdaqGS:ILMN) latest earnings update (29 December 2019), I found it beneficial to...
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
GenapSys said that the new funds will be used for global expansion, particularly in Asia where it says its iPad-sized, next-generation sequencer might be used to help to track the expanding coronavirus outbreak.
Illumina, Inc. (NASDAQ:ILMN) shares fell 9.2% to US$290 in the week since its latest full-year results. Illumina...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20 years later, Mammoth Biosciences is hoping to do the same thing for gene editing tools. The company, co-founded by Jennifer Doudna, who did some of the pioneering work to discover the gene editing enzyme known as CRISPR, has just raised $45 million as it looks to bring to market products that can be used not only for disease detection, but are more precise editing tools for genetic material.
A new U.S. task force led by Health and Human Services chief Alex Azar is the latest effort by officials to prepare for additional cases of the novel coronavirus in the U.S.
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Illumina (ILMN) delivered earnings and revenue surprises of 6.92% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Late Wednesday, Illumina reported adjusted earnings of $1.70 per share on $953 million in sales for its fourth quarter ended Dec. 29. The results prodded ILMN stock down a fraction.